ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
K Silence, T Dreier, M Moshir, P Ulrichts, SME Gabriels… - MAbs, 2014 - Taylor & Francis
Overexpression of CD70 has been documented in a variety of solid and hematological
tumors, where it is thought to play a role in tumor proliferation and evasion of immune …
tumors, where it is thought to play a role in tumor proliferation and evasion of immune …
Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies
L Huyghe, A Van Parys, A Cauwels… - EMBO Molecular …, 2020 - embopress.org
Systemic toxicities have severely limited the clinical application of tumor necrosis factor
(TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of …
(TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of …
Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling
A Hultberg, V Morello, L Huyghe, N De Jonge… - Cancer research, 2015 - AACR
Hepatocyte growth factor (HGF) and its receptor MET represent validated targets for cancer
therapy. However, HGF/MET inhibitors being explored as cancer therapeutics exhibit …
therapy. However, HGF/MET inhibitors being explored as cancer therapeutics exhibit …
[HTML][HTML] Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
B Van Den Eeckhout, L Huyghe, S Van Lint… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Clinical success of therapeutic cancer vaccines depends on the ability to mount
strong and durable antitumor T cell responses. To achieve this, potent cellular adjuvants are …
strong and durable antitumor T cell responses. To achieve this, potent cellular adjuvants are …
Influence of cinaciguat on gastrointestinal motility in apo‐sGC mice
SMR Cosyns, L Huyghe, R Thoonen… - …, 2014 - Wiley Online Library
Abstract Background Cinaciguat (BAY 58‐2667), an NO‐and heme‐independent sGC
activator, was shown to be more effective when the heme‐group of sGC is oxidized in …
activator, was shown to be more effective when the heme‐group of sGC is oxidized in …
[PDF][PDF] Study of molecular and immunological factors that determine the sensitivity to the antitumor effect of Tumor Necrosis Factor
L Huyghe - 2008 - biblio.ugent.be
The development of a tumor vasculature is essential for the survival, growth and metastasis
of solid tumors. Folkman and colleagues postulated already in the early 1970s that it should …
of solid tumors. Folkman and colleagues postulated already in the early 1970s that it should …
Abstract# 5074: Tenfold dose reduction of the in vivo cancer-destroying dose of TNF using combination therapies with PI3K inhibitors or NKT activators
P Brouckaert, L Huyghe, D Elewaut, P Sonveaux… - Cancer Research, 2009 - AACR
Abstract Tumor Necrosis Factor (TNF) is a cytokine with potent antitumor effects. TNF exerts
this cancer-destroying effect by interacting with the TNFR1 on endothelial cells and …
this cancer-destroying effect by interacting with the TNFR1 on endothelial cells and …
[CITATION][C] NKT cells contribute to tumor destruction by TNF
L Huyghe, A Goethals, J Hostens… - ACTA CLINICA …, 2008 - biblio.ugent.be
NKT cells contribute to tumor destruction by TNF Universiteit Gent Add publications and
datasets Lists Sign in Academic Bibliography Search 200 years of publications by Ghent …
datasets Lists Sign in Academic Bibliography Search 200 years of publications by Ghent …
[CITATION][C] Tenfold dose reduction of the in vivo cancer-destroying dose of TNF using combination therapies with PI3K inhibitors or NKT activators
PG Brouckaert, L Huyghe, D Elewaut… - Proc. Amer. Assoc …, 2009 - dial.uclouvain.be